Skip to main content
C
CorpDigest
Search

Sanofi S.A.

Pharmaceuticals and BiotechnologyFounded 2004
Reviewed by Swet Parvadiya
Company data updated: October 2026
Independent Editorial Analysis
9 historical events · Editorial analysis

Sanofi Company Profile: Revenue, Business Model & Strategy

Research depth: 9 milestones · 10 FAQs

Sanofi reported ~$49.3 billion (EUR43.626 billion) of net sales in FY2025, up 9.9% at constant exchange rates, with Dupixent contributing ~$17.7 billion (EUR15.7 billion). Belén Garijo has been CEO since the April 29, 2026 AGM, and the company had 74,846 employees at year-end 2025.

How Sanofi makes money: Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems.

Revenue & employeesCEO historyFoundersBusiness model
Annual Revenue (FY2025)~$49.3B
Employees74,846
CEOBelén Garijo
Founded2004
IndustryHealthcare
By Swet ParvadiyaLast reviewed:
Share
Data sources: annual reports, SEC filings, methodology
Industry:Pharmaceuticals and Biotechnology

Sanofi S.A. key figures

Sanofi S.A. had revenue of ~$49.3B for fiscal year 2025, up 6.2% from FY2024. Net income was ~$8.8B, a net margin of 17.9%.

Source: Sanofi Q4 and FY2025 results · Last reviewed October 2026

Revenue growth, FY2021 to FY2025
+2.7% a year
Compound annual rate, ~$44.3B to ~$49.3B
Peak revenue year
FY2025
The latest annual year is the highest in this series
Revenue per employee
~$658,651
FY2025 revenue divided by 74,846 employees; headcount may use another date
Current chief executive
Belén Garijo
In the role since 2026
Documented transactions
4
Between 2004 and 2025
Founded
2004
22 years ago
Where was Sanofi founded?
Sanofi was founded in Paris, France in 2004.
When did Sanofi start?
Sanofi was founded in 2004.
Who founded Sanofi?
Sanofi was founded by Jean-François Dehecq and René Sautier.
How old is Sanofi?
Sanofi is 22 years old as of 2026.
In-Depth Analysis
182 words · 1 min read

Modern Sanofi took shape in 2004 when Sanofi-Synthélabo won a hostile takeover of the larger Franco-German group Aventis, with the French government favoring a domestic deal over a rival approach from Novartis.

The Lantus Patent Cliff

For years Sanofi relied on Lantus, its long-acting insulin. US exclusivity ended in 2015, competing insulins such as Eli Lilly's Basaglar arrived, and diabetes sales declined, prompting a search for new growth.

Play to Win

Paul Hudson became CEO in 2019 and launched 'Play to Win', stopping most diabetes and cardiovascular research and focusing on immunology, vaccines and rare diseases.

Dupixent

Dupixent, developed with Regeneron and first approved in 2017, grew into Sanofi's largest product, with ~$17.7 billion (EUR15.7 billion) of sales in 2025 and more than $5.65 billion (EUR5 billion) in Q2 2026 alone.

Opella and the 2026 Leadership Change

In April 2025 Sanofi sold a 50% controlling stake in its consumer health unit Opella to CD&R, keeping 48.2%. In February 2026 the board declined to renew Hudson's mandate, and former Merck KGaA CEO Belén Garijo took over after the April 29, 2026 AGM.

Table of Contents

Sanofi S.A. Key Facts

CompanySanofi S.A.
Annual revenue change+6.2% (FY2024–FY2025)
Financials~$49.3B (FY2025, last reviewed October 2026)
Market Cap$100.0B
FY2025 net income~$8.8B
Last reviewedBy Swet Parvadiya, Founder & Editor - October 2026
Founded2004
Founder(s)Jean-Francois Dehecq, Rene Sautier
CEOBelén Garijo
HeadquartersParis, France
IndustryPharmaceuticals and Biotechnology
Employees74,846+
TickerSAN

Sanofi Company Profile: Revenue, Business Model & Strategy

"Sanofi now earns more than a third of its sales from one antibody, Dupixent, and in 2026 its board replaced the CEO who built that strategy with the former head of Merck KGaA."

Why Sanofi S.A. Wins

Sanofi wins when Dupixent keeps adding indications and patients, and when its vaccine scale and rare disease portfolio deliver steady cash to fund the next wave of medicines.

Sanofi S.A. operates in a competitive market alongside Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, GSK plc, Merck & Co., Inc., Johnson & Johnson. Analysts frequently compare Sanofi S.A. and Pfizer Inc. due to their overlapping products, target markets, and strategic positioning.

Sanofi reported ~$49.3 billion (EUR43.626 billion) of net sales in FY2025, up 9.9% at constant exchange rates, with Dupixent contributing ~$17.7 billion (EUR15.7 billion). Belén Garijo has been CEO since the April 29, 2026 AGM, and the company had 74,846 employees at year-end 2025.

Revenue

~$49.3B

Founded

2004

Employees

75K+

Market Cap

$100.0B

Author: CorpDigest Research DeskCompany Research

Explore Sanofi In Depth

Detailed research across every dimension of Sanofi — history, financials, leadership, and strategy.

Company History

Sanofi S.A. is headquartered in Paris and listed on Euronext Paris (SAN) and Nasdaq (SNY ADRs). It employed 74,846 people at the end of 2025.

Full Sanofi history →

Revenue & Financials

Sanofi had ~$49.3B in revenue for fiscal year 2025. Data covers 5 fiscal years. Market capitalization stands at approximately $100B.

Sanofi financials →

Founders

Sanofi was founded by Jean-Francois Dehecq, Rene Sautier in 2004. Explore each founder's background, motivations, and their role in building the company.

Sanofi founders →

CEO & Leadership

Sanofi is currently led by Belén Garijo. Explore the full CEO history — leadership transitions, tenures, and the strategic decisions of each chief executive.

Sanofi CEO history →

Business Model

Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems.

How Sanofi makes money →

Acquisitions

Sanofi has completed 4 documented acquisitions. Explore the full acquisition history and strategic rationale behind each deal.

Sanofi acquisitions →

Competitive Strategy

Sanofi's strategy, set under Paul Hudson's 2019 'Play to Win' plan and now being tightened by Belén Garijo, is to concentrate on immunology, rare diseases, neurology and vaccines.

Sanofi strategy →

Related Company Comparisons

CorpDigest Research Desk

 Research Profile

Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.

About the Author →Our Methodology →

Frequently Asked Questions About Sanofi

How does Sanofi make money?

Sanofi sells prescription medicines and vaccines. In 2025, Dupixent brought in ~$17.7 billion (EUR15.7 billion), vaccines ~$8.93 billion (EUR7.9 billion), newer pharma launches ~$4.41 billion (EUR3.9 billion) and other established medicines ~$18.2 billion (EUR16.1 billion), for total net sales of ~$49.3 billion (EUR43.6 billion). About half of sales came from the United States.

Who is the CEO of Sanofi?

Belén Garijo is CEO of Sanofi. She took up the role after the April 29, 2026 annual general meeting, having previously run Merck KGaA and spent 15 years at Sanofi earlier in her career. She succeeded Paul Hudson (CEO from 2019), whose mandate the board declined to renew in February 2026; Olivier Charmeil served as interim CEO.

Who owns Sanofi?

Sanofi is a publicly traded company listed on Euronext Paris (SAN) with ADRs on Nasdaq (SNY). Its shares are mainly held by institutional investors; L'Oréal has long been the largest single shareholder with a stake of roughly 9%.

Who are Sanofi's competitors?

Sanofi's main competitors include Roche, Novartis, Pfizer, AstraZeneca, GSK, Merck & Co. and Johnson & Johnson. In immunology it competes with AbbVie, Eli Lilly and Amgen, and in vaccines with GSK, Pfizer, Merck and Moderna.

What was Sanofi's revenue in 2025?

Sanofi reported FY2025 net sales of ~$49.3 billion (EUR43.626 billion), up 9.9% at constant exchange rates and 6.2% reported, and net income attributable to shareholders of ~$8.83 billion (EUR7.813 billion).

How did Sanofi perform in Q2 2026?

Q2 2026 sales rose 17.8% at CER to ~$13.1 billion (EUR11.6 billion) and business EPS rose 33.3% at CER to EUR2.09. Dupixent sales grew 37.6% to ~$5.88 billion (EUR5.2 billion), and Sanofi raised its 2026 guidance to sales growth of around 10% at CER.

What happened to Sanofi's consumer health business Opella?

On April 30, 2025, Sanofi closed the sale of a 50.0% controlling stake in Opella to CD&R. Sanofi kept 48.2% and Bpifrance took 1.8%.

How many employees does Sanofi have?

Sanofi had 74,846 employees at December 31, 2025, according to its FY2025 annual report.

What is Sanofi best known for?

Sanofi is historically known as a global leader in diabetes treatments (like Lantus) and vaccines, though its current massive revenue driver is the blockbuster immunology drug Dupixent.

When was Sanofi founded?

The modern Sanofi was officially formed in 2004 through a massive $65 billion merger between Sanofi-Synthélabo and Aventis.

Analysis: How Sanofi S.A. Makes Money

Deep dive into the Sanofi S.A. business model, revenue streams, and strategic moats in 2026.

Competitor Benchmarking

Sanofi S.A. vs GSK plc

Compare

Related Companies to Sanofi S.A.

Johnson & Johnson
healthcare
F. Hoffmann-La Roche AG
Healthcare
Pfizer Inc.
Technology
AstraZeneca PLC
Pharmaceuticals
Novartis AG
Pharmaceuticals
GSK plc
TechnologyCompare

Compare Sanofi S.A. With

S
G
Sanofi S.A. vs GSK plc
Strategic Head-to-Head

Financial data on this page is sourced from SEC EDGAR filings, official earnings releases, and verified press statements. Revenue figures are reviewed and updated periodically. Read our full data methodology ->

Primary source: www.sanofi.com/assets/dotcom/content-app/publications/annual

Explore More Brand Histories

This corporate intelligence report on Sanofi S.A. compiles data from verified filings. Explore more detailed brand histories and company histories in the global Pharmaceuticals and Biotechnology marketplace.

Full Company Directory ->

Editorial Methodology

Company Research

We use company filings, annual reports, company statements and press reports, with primary sources preferred where available. Each financial row shows its recorded source. Full-year figures are separated from annualized run-rates, partial periods and forecasts; unaudited figures carry a label. Source detail varies by company, so check the linked material when the reporting basis matters.

1. Primary Sources

Public companies may provide filings and annual reports. Private-company figures may come from statements or press coverage. A missing figure stays missing, and a source link should identify where its number came from.

2. Expert Curation

We organize company records and review claims for strategic context, source quality and clarity. Pages show a review date where one is recorded.

3. Multi-Pass Audit

Technical checks flag inconsistent figures and missing links. Editorial review of the underlying source remains necessary for claims those checks cannot verify.

Swet Parvadiya
SEC filings & public records methodology
Sourced from public financial records

Explore Related Pages for Sanofi S.A.

History & FailuresTimeline, setbacks, and key milestonesBusiness ModelHow they make money and market productsFinancialsRevenue history and fiscal metricsCompetitive StrategyRivals, benchmarks, and SWOT analysis

Sources & References

The data and narrative synthesized in this intelligence report were verified against primary sources:

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). Sanofi S.A. from https://corpdigest.com/company/sanofi

MLA Format

CorpDigest. "Sanofi S.A." CorpDigest, 2026, https://corpdigest.com/company/sanofi.

Chicago Format

CorpDigest. "Sanofi S.A." CorpDigest. 2026. https://corpdigest.com/company/sanofi.

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Pfizer

View Competitor Intelligence
Competitor

Novartis

View Competitor Intelligence
Competitor

Roche

View Competitor Intelligence
Competitor

Astrazeneca

View Competitor Intelligence
Competitor

Gsk

View Competitor Intelligence
Competitor

Merck

View Competitor Intelligence

Explore Sanofi

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.